Oxford Technology 2 VCT PLC
20 June 2001
Oxford Technology 2 VCT has invested £150,000 in Prolysis Ltd as part of a
larger round that raised a total of £700,000 for the company.
Prolysis Ltd was established in 1998 as an antibiotic discovery company to
exploit high throughput screening technology developed by Professor Jeffrey
Errington of the Dunn School of Pathology, University of Oxford. The patented
screening technology enables chemical libraries to be rapidly checked for new
compounds with specific activity against a series of novel bacterial targets.
The sensitivity of the screen allows suboptimal compounds to be identified
which can then be optimised using combinatorial chemistry.
The purpose of the investment is to provide the company with working capital
to enable it to achieve significant milestones over the next twelve months.
For further information, please contact Oxford Technology 2 VCT on 01865
784466.
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.